Pegylated Dickeya Chrysanthemi L-asparaginase Uses, Dosage, Side Effects and more
Pegylated Dickeya Chrysanthemi L-asparaginase is under investigation in clinical trial NCT02257684 (A Dose Confirmation and Pharmacokinetic Study of Pegylated Dickeya Chrysanthemi L-asparaginase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)).
| Trade Name | Pegylated Dickeya Chrysanthemi L-asparaginase |
| Generic | Pegcrisantaspase |
| Pegcrisantaspase Other Names | Asparec, Mpeg-r-crisantaspase, Pegcrisantaspase, Pegylated dickeya chrysanthemi l-asparaginase, Pegylated erwinia chrysanthemi l-asparaginase |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
